This Growth Hormone Drug Could Be a Boost For Pfizer

Pfizer (NYSE: PFE) and its partner OPKO Health (NASDAQ: OPK) recently submitted additional data to the U.S. Food and Drug Administration (FDA) on their Biologics License Application (BLA) for their drug known as somatrogon, which treats children with growth hormone deficiency (GHD).

Since the FDA now has to review the additional data that was submitted, it pushed back the decision date to January 2022.

With a potential FDA approval just a few months away, let's take a look at the efficacy of somatrogon and its sales potential.

Continue reading

Source Fool.com